← FDA DRUG APPROVALS

FDA ANDA · ANDA214688

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

Sponsor: GLENMARK PHARMS LTD

APPLICATION
ANDA214688
TYPE
ANDA
ORIGINAL APPROVAL
2023-03-21
LATEST ACTION
2023-03-21
ROUTE
TOPICAL
DOSAGE FORM
AEROSOL, FOAM
MARKETING STATUS
Discontinued

Products

CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATEDiscontinued
BETAMETHASONE DIPROPIONATE 0.064%, CALCIPOTRIENE 0.005% · AEROSOL, FOAM · TOPICAL

Approval history

2023-03-21UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →